Knowledge Tree
Relations (1)
related 2.58 — strongly supporting 5 facts
Ketamine and serotonergic psychedelics are linked as emerging psychiatric treatments for depression [1] that share significant phenomenological experiences [2] and neural signal signatures despite their distinct pharmacological profiles [3]. They are frequently studied together in clinical research regarding rapid-acting antidepressant mechanisms {fact:1, fact:5}.
Facts (5)
Sources
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org 4 facts
claimSerotonergic psychedelic and ketamine experiences exhibit significant phenomenological overlap.
claimRecent neuroimaging research indicates that despite pharmacological differences, serotonergic psychedelics and ketamine share neural features, specifically heightened neural signal diversity, reduced within-network connectivity, and enhanced between-network connectivity.
referenceJohnston et al. provided an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment involving ketamine and serotonergic psychedelics, published in Neuropharmacology in 2023.
claimKetamine and serotonergic psychedelics are re-emerging as potential treatments for depression, generating considerable interest.
Neuroimaging in psychedelic drug development: past, present, and ... nature.com 1 fact
claimKetamine, 3,4-Methylenedioxymethamphetamine (MDMA), and ibogaine are psychoactive substances that hold promise for psychiatric treatment alongside classic serotonergic psychedelics.